Equities

BRAIN Biotech AG

BRAIN Biotech AG

Actions
Basic MaterialsChemicals
  • Price (EUR)2.93
  • Today's Change-0.02 / -0.68%
  • Shares traded13.02k
  • 1 Year change-28.19%
  • Beta1.1723
Data delayed at least 15 minutes, as of Nov 14 2024 16:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BRAIN Biotech AG, formerly known as BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company develops and brings to market biological ingredients for Nutrition & Health, SkinCare and Industrial BioSolutions. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.

  • Revenue in EUR (TTM)56.26m
  • Net income in EUR-8.77m
  • Incorporated2000
  • Employees309.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Plenum AG30.10m653.04k13.24m144.0020.272.285.650.43980.38470.384717.733.431.9659.665.28184,671.704.244.495.765.8083.0684.812.163.062.5621.520.237525.8819.4620.80-17.7436.03----
Libero football finance AG50.00k-166.22k16.80m7.00------336.00-0.0042-0.00420.00130.000.1908--0.3648---63.42-22.99-66.09-298.96100.00---332.44-12.57---97.361.00---65.97--99.04------
11 88 0 Solutions AG56.31m-1.62m21.77m483.00--6.736.800.3867-0.0733-0.07332.340.12332.69--10.23109,550.60-7.76-9.42-19.28-18.3741.4242.31-2.89-4.70---0.51260.3169--1.855.86-23.00---28.73--
Syzygy AG69.92m2.37m38.07m554.0015.940.88625.490.54450.17690.17695.223.180.8057--4.34118,711.402.90-0.07144.25-0.100220.2026.503.61-0.1204--8.190.3645--1.601.7461.13---10.56--
Deufol SE304.75m-3.70m44.69m2.33k--0.3531.640.1467-0.4311-0.431135.7714.451.096.748.73136,904.80-1.131.52-1.532.0962.9460.92-1.041.580.8060.84380.410330.378.262.090.676310.23-8.2710.76
Exasol AG36.81m-3.50m63.17m193.00--15.31--1.72-0.118-0.1181.300.15351.54--24.69190,709.90-14.61-50.76-15.31-55.7294.0294.44-9.51-71.5129.92--0.00--5.8914.6845.27---45.44--
BRAIN Biotech AG56.26m-8.77m64.45m309.00--3.94--1.15-0.4016-0.40162.580.74860.7834----170,487.90-12.31-10.71-15.45-14.4656.6656.16-15.71-17.47---2.340.00--11.7914.12-25.63--14.47--
Bertrandt AG1.22bn17.05m161.78m14.42k9.45--2.050.13271.691.69120.67--------85,425.40--2.25--2.9187.7890.141.402.03--4.10--189.1314.712.5544.05-8.47-12.71-9.71
Data as of Nov 14 2024. Currency figures normalised to BRAIN Biotech AG's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.